Revenue from Contracts with Customers Revenue from Contracts with Customers (Notes)

3 Months Ended

Apr. 01, 2022

Revenue from Contract with Customer [Abstract]

Revenue from Contract with Customer [Text Block]

3. Revenue from Contracts with Customers

Product Sales Revenue

See Note 13 for presentation of the Company's net sales by product family.

Reserves for variable consideration

The following table reflects activity in the Company's sales reserve accounts:

	Rebates and Chargebacks		Product Returns		Other Sales Deductions		Total
Balance as of December 25, 2020	$	196.5	$	26.6	$	12.3	$	235.4
Provisions (1)	488.0		25.7		13.0		526.7
Payments or credits	(442.9)		(10.0)		(14.9)		(467.8)
Balance as of March 26, 2021	$	241.6	$	42.3	$	10.4	$	294.3
Balance as of December 31, 2021	$	241.8	$	21.5	$	9.5	$	272.8
Provisions	370.8		2.4		9.7		382.9
Payments or credits	(412.0)		(4.3)		(10.0)		(426.3)
Balance as of April 1, 2022	$	200.6	$	19.6	$	9.2	$	229.4

(1)Provision for returns decreased by $23.3 million driven by the Specialty Brands segment primarily related to a discrete return of product during the three months ended March 26, 2021.

Product sales transferred to customers at a point in time and over time were as follows:

	Three Months Ended
	April 1, 2022		March 26, 2021
Product sales transferred at a point in time	79.5	%	75.7	%
Product sales transferred over time	20.5		24.3

Transaction price allocated to the remaining performance obligations

The following table includes estimated revenue from contracts extending greater than one year for certain of the Company's hospital products that are expected to be recognized in the future related to performance obligations that were unsatisfied or partially unsatisfied as of April 1, 2022:

Remainder of Fiscal 2022	$	69.6
Fiscal 2023	71.2
Fiscal 2024	17.5
Thereafter	0.3

Product Royalty Revenues

The Company licenses certain rights to Amitiza® (lubiprostone) ("Amitiza") to third parties in exchange for royalties on net sales of the product. The Company receives a double-digit royalty based on a percentage of the gross profits of the licensed products sold during the term of the agreements. The Company recognizes such royalty revenue as the related sales occur. The associated royalty revenue recognized was as follows:

	Three Months Ended
	April 1, 2022		March 26, 2021
Royalty revenue	$	20.0	$	35.4